Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00599820
Verified January 2008 by Asociación para Evitar la Ceguera en México. Recruitment status was: Active, not recruiting
Intravitreal Bevacizumab is an effective treatment for choroidal neovascularization secondary to Angioid Streaks
Condition or disease
Angioid StreaksChoroidal Neovascularization
Drug: Intravitreal Bevacizumab
A consecutive case series of patients with angioid streaks that developed subfoveal choroidal neovascularization were treated with a primary 2.5 mg injection of Bevacizumab (Avastin) intravitreally. All patients were evaluated with BCVA at 1, 2 , 4 and 12 weeks and OCT and fluoresceine angiography at month 1 and 3. (Patients will be follow 6 months)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
Child, Adult, Senior
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Clinical diagnosis of Angioid Streaks
Choroidal neovascularization associated
Untreated patients or patients treated once with PDT
Ocular surgery excepting uncomplicated phacoemulsification